[1] 施春雷, 张雪艳, 韩宝惠, 赵家美. 血清CEA、CYFRA21-1、NSE联合检测在肺癌中的诊断价值 [J]. 诊断学理论与实践 2003.doi:10.3969/j.issn.1671-2870.2003.03.011
[2] LU Renquan, 郭林, XU Xiaofeng, LU Renquan, GUO Lin, XU Xiaofeng. 胃肠道恶性肿瘤患者血浆肿瘤型M2-丙酮酸激酶的测定及其临床价值 [J]. 检验医学 2008.doi:10.3969/j.issn.1673-8640.2008.04.010
[3] 白晓卉, 孔丽, 张爱荣, 贾继辉, 张魏芳, 唐伟, 于修平, BAI Xiao-hui, KONG Li, ZHANG Ai-rong, JIA Ji-hui, ZHANG Wei-fang, TANG Wei, YU Xiu-ping. M2-PK蛋白在宫颈及癌变组织中的差异表达 [J]. 山东大学学报（医学版） 2006.doi:10.3969/j.issn.1671-7554.2006.10.003
[4] Mazlurek S, Bosckhek CB, Hugo F. Pgrubate Kinase type M2 and its role in tumor growth and spreeding [J]. Sen in Cancer Biol 2005, 15(04).
[5] Mazurek S, Zwerschke W, Jansen Durr P, Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. [J]. Oncogene 2001, 47(47).
[6] Mazurek S, Grimm H, Oehmke M. Tumor M2-PK and glutam imolytic enzymes in the metabolic shift of tumor tells [J]. Anticancer Research 2000, 20(6D).
[7] Mazure R S, Grimm H, Boschek CB. Pyruvate kinase type M2:a crossroad im the tumor metabolome [J]. British Journal of Nutrition 2002, 87(z1).
[8] Hugo F, Fischer G, Eigenbrodt E. Quantitative detection of tumor M2-PK in serum and plasma. [J]. Anticancer Research: International Journal of Cancer Research and Treatment 1999, 4A(4A).
[9] Lufiner D, Mesterharm J, Akrivakis C. Tumor type M2 pyruvate Kinase expression in advanced breast cancer [J]. Anticancer Research 2000, 20(6D).
[10] Schneider J, Neu K, Veleorsky H G. Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients:a pilot study [J]. Cancer Letters 2003, 193(01).
[11] Schneider J, Veleovsky H G, Mort H. Comparison of the tumor markers tumor M2-PK, CEA, CYERA21-1, NSE and SCC in the diagnosis of lung cancer [J]. Anticancer Research 2000, 20(6D).
[12] Hudelist G, Kostler W, Czerwenka K, Kubista E, Singer CF. [J]. Methods and findings in experimental and clinical pharmacology 2004.
[13] Schneider J, Bitterlich N, Schulze G. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. [J]. Anticancer Research: International Journal of Cancer Research and Treatment 2005, 3A(3A).
[14] Oremek GM, Muller R, Sapoutzis N, Wigand R. [J]. Anticancer Research: International Journal of Cancer Research and Treatment 2003.
[15] Oremek GM, Gerstmeier F, Sauer Eppel H, Sapoutzis N, Wechsel HW. [J]. Anticancer Research: International Journal of Cancer Research and Treatment 2003.
[16] Schneider J, Morr H, Veleovsky H G. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases [J]. Cancer Petect Prey 2000, 24(06).
[17] Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. [J]. Clinical and experimental medicine 2003, 4(4).
[18] Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. [J]. European journal of gastroenterology and hepatology 2007, 3(3).
[19] Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. [J]. The British journal of cancer 2004, 5(5). |
